Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Pharmacy

Background:

• Epilepsy frequently co-occurs with psychiatric disorders, notably depression, significantly impairing patient quality of life.
• The efficacy of antiepileptic treatments can be diminished in patients with epilepsy and comorbid depression.

Purpose of the Study:

• To investigate the pharmacokinetic and pharmacodynamic interactions between antiepileptic drugs (AEDs) and antidepressants.
• To provide guidance on the safe and effective co-administration of these drug classes in patients with epilepsy and depression.

Main Methods:

• Review of experimental studies on drug interactions in seizure models.
• Analysis of clinical data on pharmacokinetic interactions between enzyme-inducing AEDs and various antidepressants.
• Evaluation of the impact of selective serotonin reuptake inhibitors (SSRIs) on AED metabolism.

Main Results:

• Antidepressants can modulate anticonvulsant activity, with effects ranging from potentiation to reduction.
• Pharmacokinetic interactions are significant; some antidepressants reduce plasma concentrations of AEDs, while others (like SSRIs) can increase AED levels.
• Specific antidepressants, such as bupropion and mianserin, may decrease seizure threshold or reduce AED efficacy.

Conclusions:

• Preclinical data suggest that antidepressants neutral or potentiating to anticonvulsant action are preferable for co-administration.
• Avoidance of antidepressants known to decrease seizure threshold or impair AED efficacy is crucial for patients with epilepsy.